This study systematically assessed the effectiveness of lifestyle interventions on glycemic indicators among adults (≥18years) without IGT or diabetes. Randomized controlled trials using physical activity (PA), diet (D), or their combined strategies (PA+D) with follow-up ≥12 months were systematically searched from multiple electronic-databases between inception and April 17, 2015. Outcome measures included fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin (FI), homeostasis model assessment-estimated insulin resistance (HOMA-IR), and bodyweight. Included studies were divided into low-range (FPG <5.5mmol/L or HbA1c <5.5%) and high-range (FPG ≥5.5mmol/L or HbA1c ≥5.5%) groups according to baseline glycemic levels. Seventy-one studies met inclusion criteria. Random-effect models demonstrated that compared with usual care, lifestyle interventions achieved significant reductions in FPG (−0.14mmol/ L[95%CI, −0.18, −0.09]), HbA1c (−0.05%[−0.08, −0.03]), FI (%change: −15.18%[− 20.01-10.35]), HOMA-IR (%change: −22.66%[−29.19, −16.14]), and bodyweight (%change: −4.00% [−4.73, −3.26]). The same effect sizes in FPG reduction (0.08) appeared among both low-range and high-range groups. Similar effects were observed among all groups regardless of lengths of follow-up. D and PA+D interventions had larger effects on glucose reduction than PA alone. Lifestyle interventions significantly improved FPG, HbA1c, FI, HOMA-IR, and bodyweight among adults without IGT or diabetes, and might reduce progression of hyperglycemia to type 2 diabetes mellitus.
Introduction
Diabetes imposes a large burden on human health, society, and the economy due to its wideranging complications and extensive treatment costs [1] . Physical inactivity, unhealthy diet, and obesity are well-established risk factors for type 2 diabetes mellitus, and structured lifestyle interventions incorporating behavior change, dietary modifications, and regular moderate-intensity physical activity resulting in modest weight reduction have been shown to reduce type 2 diabetes mellitus incidence [2] [3] [4] . However, for practical reasons of statistical power and study cost, the major diabetes prevention trials have focused on the subset of individuals with impaired glucose tolerance (IGT) rather than these other risk factors [2] [3] [4] . This has raised considerable debate about whether structured lifestyle interventions should be limited to people with IGT or could be applied more broadly to the population that includes individuals without IGT.
In studies among persons with normal glucose levels, researchers need large sample sizes and long follow-up periods for exploring the effect of lifestyle interventions on reducing the incidence of diabetes, making these studies costly and difficult to conduct [5] . However, a systematic review and meta-analysis of aggregate data from studies of lifestyle interventions among people without IGT may provide evidence of the impact of such interventions on risk factors for diabetes or on the potential to prevent type 2 diabetes mellitus.
We conducted a systematic review to assess the aggregated impact of lifestyle interventions on glycemic indicators among adults (≥18 years) without IGT or diabetes.
Methods

Data source and searches
We developed a study protocol following Cochrane Collaboration standards [6] . We systemically searched MEDLINE, EMBASE, CINAHL, Web of Science, Cochrane Library, and Psychlnfo databases, from inception to April 17, 2015. Medical Subject Headings, text words, and search strategies are available from the authors. We examined reference lists of all studies and relevant reviews for potential additional studies. We directly contacted authors to clarify unclear data.
Study selection
We selected randomized controlled trials (RCTs) published in any language that examined lifestyle strategies involving physical activity (PA), diet (D), or their combination (PA+D) among adults (≥18 years), and with at least 1 glycemic indicator reported as the intervention outcome (e.g., fasting plasma glucose [FPG] , glycated hemoglobin A1c [HbAlc], fasting insulin [FI] , and homeostasis model assessment-estimated insulin resistance [HOMA-IR]) with a follow-up interval ≥12 months. Included studies investigated individuals without IGT or diabetes. We excluded all studies among individuals with IGT confirmed by 2-hour oral glucose tolerance test (OGTT) (75g). We included studies regardless of baseline glucose levels. However, we classified studies with mean baseline FPG <5.5mmol/L or HbA1c <5.5% as the low-range group, and with mean baseline FPG ≥5.5mmol/L or HbA1c ≥5.5% as the high-range group, and analyzed data as a whole and by glycemic level groups.
Data extraction and quality assessment
One primary reviewer and a secondary reviewer independently assessed the manuscript titles and abstracts for inclusion. If any disagreement occurred between the 2 reviewers, a third reviewer reviewed the item, and consensus was reached by a discussion. The study team extracted data regarding demographic and intervention characteristics. Primary outcomes in this review included FPG, A1C, FI, and HOMA-IR. In our synthesis models, we used percent changes in FI and HOMA-IR, rather than raw values, to account for nonstandardized insulin measurements. We also examined percent body weight change from baseline.
In our review, all interventions were classified into 3 categories: PA, D, and their combination. PA interventions included any strategy to increase physical activity levels using counseling, exercise prescription, or a supervised or unsupervised exercise program. The D interventions included any strategy used to reduce or control calorie intake, such as very low-calorie diet (<800 kcal/d) or low-calorie diet (800 to 1500 kcal/d). PA+D interventions usually also employed a behavioral modification component, such as counseling, education, cognitive-behavioral therapy, or social support.
We assessed study quality by examining potential selection, attrition, and detection bias [6] . We excluded from our main analyses studies of poor quality (e.g., studies with attrition ≥30%). However, we conducted a sensitivity analysis to compare pooled effects between studies with potentially significant bias and those without. For example, for those studies with attrition ≥30%, data were not used in our primary meta-analyses, but were used in our sensitivity analyses.
Data Synthesis and Analysis
If 2 or more studies with similar intervention and comparison groups reported a similar outcome of interest, we conducted a meta-analysis to determine pooled effects. We calculated the mean difference between baseline and follow-up measures for the intervention and comparison groups (delta I and delta C) and the standard error of each difference. We used 3 data synthesis strategies to estimate pooled effects: stratification by glycemic levels, stratification by follow-up duration, and stratification by type of intervention.
We used the DerSimonian and Laird random-effects model [7] to determine pooled effects. We used meta-regression to determine whether various study-level characteristics (mean age, follow-up duration, duration of the intervention, number of intervention contacts, attrition, and year of publication) affected the between-group change in FPG, and we examined interaction terms for all models. We also used meta-regression to test if there is an association between the magnitude of body weight change and the magnitude of FPG change. The meta-regression was conducted using SPSS (version 20.0, Armonk, NY: IBM Corp.). We used the chi-squared test to examine heterogeneity, and Cochrane Review Manager software (version 5.1; Copenhagen, Denmark) to calculate pooled effects. Effect size was defined by the mean difference between delta I and delta C divided by the standard deviation of the mean.
If a comparison group in a study used a similar approach as the intervention group, but only differed in dose, intensity, or frequency (e.g., diet plan A vs diet plan B; or swimming vs walking), we analyzed the effects of treatment in a single-arm model to determine withingroup changes (between post-intervention and pre-intervention in 1 arm) for both intervention and comparison group. These effects were also estimated by using the DerSimonian and Laird random-effects model. We did not conduct sensitivity analysis for these studies.
Results
Seventy-one studies (plus 30 additional publications based on those studies ) encompassing 13943 participants (Table 1 : range, 20 to 1089) fulfilled the inclusion criteria ( Figure 1 ). Follow-up duration ranged from 12 to 54 months. The weighted mean age of the participants was 50.9 years (range, 30.2 to 70.4 year), and mean body mass index (BMI) was 30.1 kg/m 2 (range, 23.3 to 38.7 kg/m 2 ). Mean baseline FPG, HbAlc, FI, and HOMA-IR were 5.3 mmol/L, 5.4%, 13.7 μU/ml, and 3.9, respectively. More studies took place in a community setting vs a clinic setting (52 vs 19) . Sampling methods varied, but most participants were recruited through screening programs. Attrition ranged from 0% to 60%, and was 30% or more in 15 studies [8, [20] [21] [22] 31, 44, 46, 49, 51, 57, 60, 62, 64, 70, 78] ; higher attrition rates were associated with longer follow-up duration. Thirty-eight studies with FPG <5.5mmol/L or HbA1c <5.5 % were classified as low-range glycemic level studies, and 33 studies with FPG ≥5.5mmol/L or HbA1c ≥5.5% were classified as highrange glycemic level studies (Table 1) .
We observed considerable heterogeneity in the treatments provided to both intervention and comparison groups (Table S1 and Table S2 , presented online as supplementary materials). In 27 studies, a similar approach was used in both intervention and control groups (data from these studies were synthesized by a single-arm model). In the other 44 studies, the control group received usual care (UC). In the 44 studies that compared an intervention to UC, 32 had 2 arms [8] [9] [10] 14, 17, 18, 22, [27] [28] [29] 32, 38, 40, 42, 43, 45, 47, [52] [53] [54] [55] [56] [57] [58] [59] 62, 67, 69, 70, 72, 76, 104] , 5 studies [34, 48, 71, 72, 75] had 3 arms, and 7 studies [11, 15, 30, 39, 46, 65, 77 ] had 4 arms (e.g., PA, D, PA+D and control arm). The randomization procedure was described in 43 studies (Table S2 ). Allocation concealment (i.e., blinding) was adequately reported in 26 studies. Meta-regression analyses indicated that there was no significant interaction between the between-group change in FPG and any study-level characteristic. An Egger's plot demonstrated a symmetrical shape distribution (except for 2 outliers) which supports a hypothesis of no publication bias. Table 2) . Sensitivity analyses including studies with attrition ≥30% in the model produced similar results. . Notably, intervention effects on FPG differed in absolute values (−0.08mmol/L in low-range vs −0.19mmol/L in high-range groups), but the effect sizes were the same across groups (0.08). Figure 2 and meta-analyses results in a single arm model are presented online as Table S3 .
Changes in Glycemic Indicators
Comparison According to Participant Baseline Glycemic Status (Limited to studies with attrition <30% thereafter)-In
Comparison According to Length of Follow-Up-Similar reductions in FPG
Discussion
The target population for type 2 diabetes mellitus prevention has been a topic of debate since the completion of major diabetes prevention trials [109] . The difficulty stems from observations that diabetes prevalence has increased across all segments of society [110] , yet the evidence for preventive interventions is mainly limited to persons with IGT [2] [3] [4] 111, 112] . This comprehensive review of the effects of structured lifestyle interventions yielded 3 main findings.
First, lifestyle interventions among individuals with lower risk than those with IGT and diabetes led to significant improvements in FPG, HbA1c, and FI among the full range of baseline risk, with no apparent differences measured by effect sizes between studies of persons with low-range vs high-range glycemic levels. The average magnitude of effect of 1year change in FPG of about −0.3mmol/L was about 40% of the magnitude of effect seen among persons with IGT in the U.S. Diabetes Prevention Program and the Finnish Diabetes Prevention Study, wherein lifestyle interventions resulted in a −0.2mmol/L glucose change and a 58% reduced incidence of diabetes [2] . The findings from our meta-analyses imply that the reduction in glucose may bring about similar diabetes risk reductions among population without IGT.
Second, interventions that focused only on PA without a concomitant calorie restriction had weaker effects on glycemic indicators than studies that used PA and calorie restriction, or calorie restriction alone. Third, interventions were effective across a wide variation of follow-up durations, from 1 year in 43 studies, to more than 2 years in 15 studies. Taken as a whole, our findings suggest that multi-faceted interventions combining PA and D are likely to be effective in improving glucose regulation and reducing risk for diabetes in populations with average low-range and high-range glucose levels.
Several components of lifestyle interventions have been associated with improved insulinmediated glucose transport and therein reduce insulin resistance and progression to glucose intolerance. Our findings were generally supportive of the diabetes prevention trials, which suggest that multi-component interventions, including elements of calorie restriction, PA, and behavioral support are most effective in improving glucose tolerance. However, our study did not find a significant correlation between the magnitude of weight loss and magnitude of glucose benefit. Our study found slightly weaker effects for exercise-only interventions (e.g., PA alone resulted in only 1.55% weight loss, far lower than the 5% recommended by American Diabetes Association (ADA)) [113] . In addition to non-insulin mediated glucose transport in skeletal muscle, exercise programs have been shown to have important independent effects on insulinmediated glucose regulation, markers of inflammation, insulin resistance, blood pressure, lipid profile, fitness, and improved lean-tofat mass ratio [114] . Given the fact that PA provides more benefits than just weight loss does, we need to take those extra benefits into account when we interpret our findings.
Our finding of no difference in effect by follow-up duration has potentially encouraging implications for the implementation of preventive interventions. Weight loss programs typically lead to a nadir of weight loss around 6 months followed by a gradual weight regain. Even programs with intensive attention to weight maintenance typically result in a 50% average weight regain over 3 to 4 years. Our findings that changes in glucose were as great in studies with longer (≥ 2 years) as shorter (12 months) follow-up duration suggest that the between-group improvement in FPG could persist [27] [28] [29] 42, 76] . These findings echo the extended benefits found in the Da Qing legacy study [115] . It is worth noting that most of these studies applied a PA+D strategy and included some behavioral modification components.
Our findings have important implications for the definitions of diabetes risk groups as well as clinical and public health strategies to reduce diabetes incidence. Despite strong evidence that lifestyle interventions can reduce diabetes incidence, the RCT evidence is limited to individuals with IGT. However, roughly 60% of individuals with ADA-defined pre-diabetes (measured by IFG: 5.6-6.9mmol/L) [116] and 70% of those with World Health Organization-defined intermediate hyperglycemia (measured by IFG: 6.1-7.7mmol/L) [117] do not have IGT. Individuals with isolated IFG are thought to be more affected by beta cell dysfunction than by insulin resistance and thus may be less likely to benefit from lifestyle interventions. This has fueled continued debate over who should be targeted for diabetes prevention programs. Our findings suggest that lifestyle interventions are likely to have important benefits across the full distribution of HbA1c and fasting glucose and insulin levels. However, the types of interventions that should be applied to individuals with low to moderate levels of glycemic risk are ultimately influenced by economic factors as well as the effectiveness of interventions. Economic analyses have shown that structured lifestyle interventions are considerably more cost-effective when applied to persons at the high end of the FPG and HbA1c distribution [118, 119] . Comprehensive strategies to reduce incidence likely require graduated tiers of interventions. Population-wide approaches to improve nutrition and PA will likely provide benefit to the entire population, but the magnitude of that benefit is unknown. A comprehensive approach that includes both effective populationwide approaches along with structured lifestyle interventions proven to be effective should be the goal.
There are several limitations in our study. First, only 2 studies reported the number of cases of diabetes, thus precluding even pooled estimates of the effect of the interventions on diabetes incidence rates. This reflects the fact that an intervention trial of diabetes incidence conducted among persons in the low-to high-range glucose status (from normal glucose [<5.5mmol/L] -below the IGT threshold) would require large sample sizes (i.e. several thousand participants) over several years.
Second, the large number of studies evaluated lends itself to many sources of heterogeneity, including intervention type, dose, intensity, and frequency, as well as individual risk status and levels of adherence. Our analyses of heterogeneity were conducted at the study level rather than at the individual level, and thus may have lacked sensitivity to detect the impact of such factors on glycemic indicators. Although the study population was diverse in terms of age, race/ethnicity, and sex, we were unable to test whether intervention effectiveness varied across these factors. An advantage of such diversity in our review, however, is that the effect sizes may be more reflective of real-world variation than those observed in a single large RCT.
Third, although we attempted to quantify and stratify by level of glycemic risk, there was considerable heterogeneity within studies that prevented a clean classification. As a result, there was likely considerable overlap in participant characteristics between the low-range group and high-range group in our study. A precise determination of how intervention effectiveness varies by baseline levels of glycemia may require individual level data.
Despite these limitations, this is the first comprehensive compilation of the impact of lifestyle interventions on risk for progression of dysglycemia among individuals below the IGT threshold. This comprehensive systematic review suggests that lifestyle change is important for diabetes prevention across the full spectrum of risk, complementing the major trials of diabetes incidence that focused on individuals with IGT. Decisions about how to implement prevention in practice ultimately depend on a wider set of factors, including the cost of delivering different types of interventions and the disease incidence level in the target population. For example, structured lifestyle interventions have been found to be considerably more cost-effective among persons with higher levels of HbA1c or FPG because applying interventions to persons with a higher incidence of diabetes lead to greater reduction in costs of complications and health care utilization. Thus, multiple intervention tiers may be warranted for diabetes prevention, with intense structured programs delivered to persons at higher risk, and population-targeted policies aimed at making healthier food and physical activity choices easier for the lower end of the diabetes risk distribution.
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